BSH 2023 | OPTIMAL: bortezomib-based therapy vs thalidomide-based therapy in myeloma with renal failure
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some results from the Phase II OPTIMAL trial (NCT02424851), which is comparing the efficacy of bortezomib, bendamustine and dexamethasone versus thalidomide, bendamustine and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) presenting with renal failure. Results from this study suggest that the combination with bortezomib induces a significantly deeper hematological response, although further investigation and comparison is needed. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
